Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients

Purpose: We isolated a subline (CC531M) from the CC531S rat colon carcinoma cell line, which grows and metastasizes much more rapidly than CC531S. We found, using RNA expression profiling, that one of the major changes in the CC531M cell line was a 5.8-fold reduction of the chemokine CXCL5. The purpose of this study was to determine the effect of CXCL5 expression on colorectal tumor growth and metastasis. Experimental Design: CC531 clones were generated with either knockdown or restored expression of CXCL5. These clones were inoculated in the liver of rats. In addition, in two independent cohorts of colorectal cancer patients, the level of CXCL5 expression was determined and associated to clinical variables. Results: Knockdown of CXCL5 expression in CC531S resulted in rapid tumor growth and increased number of metastasis, whereas restored expression of CXCL5 in CC531M resulted in a return of the “mild” tumor growth pattern of the parental cell line CC531S. In vitro, no difference was found in proliferation rate between clones with either high or low expression of CXCL5, suggesting that environmental interactions directed by CXCL5 determine tumor outgrowth. Finally, the importance of our findings was established for patients with colorectal cancer. We found that low expression of CXCL5 was significantly associated with poor prognosis for colorectal cancer patients. CXCL5 showed a trend (P = 0.05) for a positive correlation with intratumoral CD8+ T-cell infiltration, suggesting a possible explanation for the observed poorer prognosis. Conclusions: Our results show that CXCL5 is important in growth and development of colorectal cancer, implicating a future role in both cancer therapy and diagnosis.

[1]  H. Sarau,et al.  Chemokine-Cytokine Cross-talk , 2003, The Journal of Biological Chemistry.

[2]  J. Malm,et al.  Expression of the neutrophil‐activating CXC chemokine ENA‐78/CXCL5 by human eosinophils , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  P. Murphy,et al.  The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. , 1996, The Journal of biological chemistry.

[4]  M. Iannettoni,et al.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. , 1998, The Journal of clinical investigation.

[5]  Penny A. Johnson,et al.  Distribution of the interleukin‐8 receptors, CXCR1 and CXCR2, in inflamed gut tissue , 2000, The Journal of pathology.

[6]  G. Freeman,et al.  Ischemia-Reperfusion of Rat Myocardium Activates Nuclear Factor-&kgr;B and Induces Neutrophil Infiltration Via Lipopolysaccharide-Induced CXC Chemokine , 2001, Circulation.

[7]  Taoyong Chen,et al.  Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. , 2003, Immunology Letters.

[8]  P. Kuppen,et al.  Rat colon carcinoma cells that survived systemic immune surveillance are less sensitive to NK-cell mediated apoptosis , 2004, Clinical & Experimental Metastasis.

[9]  M. Burdick,et al.  CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.

[10]  Aihua Li,et al.  Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype , 2005, Clinical & Experimental Metastasis.

[11]  M. Cristofanilli,et al.  Manipulating the chemokine‐chemokine receptor network to treat cancer , 2007, Cancer.

[12]  H. Friess,et al.  Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. , 2006, Cancer letters.

[13]  P. Kuppen,et al.  A systemic antitumor immune response prevents outgrowth of lung tumors after i.v. rechallenge but is not able to prevent growth of experimental liver tumors , 2004, Clinical & Experimental Metastasis.

[14]  J. Merchant,et al.  ZBP-89 , Sp 1 , and Nuclear Factor-B Regulate Epithelial Neutrophil-activating Peptide-78 Gene Expression in Caco-2 Human Colonic Epithelial Cells * , 2001 .

[15]  K. Tsuneyama,et al.  High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. , 2007, Cancer research.

[16]  Gabriela Kalna,et al.  Divergent routes to oral cancer. , 2006, Cancer research.

[17]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[18]  M. Ponz de Leòn,et al.  Pathology of colorectal cancer. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[19]  U. Lippert,et al.  Human T lymphocytes and mast cells differentially express and regulate extra‐ and intracellular CXCR1 and CXCR2 , 2004, Experimental dermatology.

[20]  A. Bianchini,et al.  Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. , 2005, Biochemical pharmacology.

[21]  C. Caux,et al.  Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms1 , 2000, The Journal of Immunology.

[22]  Huqun,et al.  Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells , 2005, European journal of immunology.

[23]  Y. Iwashita,et al.  Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor‐infiltrating lymphocytes , 2006, Journal of gastroenterology and hepatology.

[24]  H. Putter,et al.  Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis , 2004, Laboratory Investigation.

[25]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[26]  Kyung Hwa Park,et al.  CXCL5 overexpression is associated with late stage gastric cancer , 2007, Journal of Cancer Research and Clinical Oncology.

[27]  D. Auld,et al.  Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[28]  H. Nielsen,et al.  Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue , 1999, The Journal of pathology.

[29]  G. Wilding,et al.  DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. , 1990, Analytical biochemistry.

[30]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[31]  Aihua Li,et al.  Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. , 2001, Clinical Cancer Research.

[32]  J. Merchant,et al.  ZBP-89, Sp1, and Nuclear Factor-κB Regulate Epithelial Neutrophil-activating Peptide-78 Gene Expression in Caco-2 Human Colonic Epithelial Cells* , 2001, The Journal of Biological Chemistry.

[33]  M. Robertson.  Role of chemokines in the biology of natural killer cells , 2002, Journal of leukocyte biology.

[34]  D. Obrand,et al.  Incidence and patterns of recurrence following curative resection for colorectal carcinoma , 1997, Diseases of the colon and rectum.

[35]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[36]  M. Burdick,et al.  CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.

[37]  J. Ting,et al.  Transfection of Macrophage Inflammatory Protein 1α into B16 F10 Melanoma Cells Inhibits Growth of Pulmonary Metastases But Not Subcutaneous Tumors1 , 2002, The Journal of Immunology.

[38]  D. Wågsäter,et al.  Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. , 2007, International journal of oncology.

[39]  C. Kelly,et al.  Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. , 1997, The American journal of physiology.

[40]  W. A. Yeudall,et al.  Down-regulation of CXCL5 inhibits squamous carcinogenesis. , 2006, Cancer research.

[41]  I. Fidler,et al.  Survival of hematogenously disseminated allogeneic tumor cells in athymic nude mice. , 1976, Transplantation.

[42]  J. Jeekel,et al.  Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumor site , 1984, International journal of cancer.

[43]  Y. Tsutsumi,et al.  Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. , 2005, Biological & pharmaceutical bulletin.

[44]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Murphy,et al.  The CXC Chemokines Growth-regulated Oncogene (GRO) α, GROβ, GROγ, Neutrophil-activating Peptide-2, and Epithelial Cell-derived Neutrophil-activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type A, Human Interleukin-8 Receptor* , 1996, The Journal of Biological Chemistry.

[46]  H. Wexler.  Accurate identification of experimental pulmonary metastases. , 1966, Journal of the National Cancer Institute.

[47]  B. van de Water,et al.  Protein Kinase C Mediates Cisplatin-Induced Loss of Adherens Junctions Followed by Apoptosis of Renal Proximal Tubular Epithelial Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.